Artal Group S.A. Buys Moderna Inc, NVIDIA Corp, Acceleron Pharma Inc, Sells Clementia Pharmaceuticals Inc, AnaptysBio Inc, bluebird bio Inc

• New Purchases: MRNA, NVDA, EPZM, ASND, MRTX, WVE, HTHT, APLS, ICPT, DTIL, ARAV,
• Added Positions: XLRN, BPMC, IFRX, MDCO, DRNA, SLDB, ATRA, SAGE, ALDR, TCDA, SELB, NKTR, TGTX, REPL, MRUS, CBAY, ACIU, KRYS, SRRK, CTMX,
• Reduced Positions: BLUE, ARRY, ARGX, NIO, FGEN, FATE, BOLD, FOLD, MDGL, ALNY, DNLI, CMRX, AUTL,
• Sold Out: CMTA, ANAB, FIXX, MNTA, MRNS, YMAB,

For the details of Artal Group S.A.'s stock buys and sells, go to https://www.gurufocus.com/guru/artal+group+s.a./current-portfolio/portfolio

1. Lexicon Pharmaceuticals Inc (LXRX) - 60,240,864 shares, 14.18% of the total portfolio.
2. Weight Watchers International Inc (WW) - 14,818,300 shares, 12.64% of the total portfolio.
3. Moderna Inc (MRNA) - 5,006,298 shares, 4.31% of the total portfolio. New Position
4. BeiGene Ltd (BGNE) - 600,000 shares, 3.35% of the total portfolio.
5. Acceleron Pharma Inc (XLRN) - 1,650,000 shares, 3.25% of the total portfolio. Shares added by 57.14%

Artal Group S.A. initiated holding in Moderna Inc. The purchase prices were between $14.45 and $23.7, with an estimated average price of $18.52. The stock is now traded at around $23.05. The impact to a portfolio due to this purchase was 4.31%. The holding were 5,006,298 shares as of .

Artal Group S.A. initiated holding in NVIDIA Corp. The purchase prices were between $127.99 and $183.94, with an estimated average price of $154.95. The stock is now traded at around $169.91. The impact to a portfolio due to this purchase was 3.19%. The holding were 420,000 shares as of .

Artal Group S.A. initiated holding in Epizyme Inc. The purchase prices were between $5.98 and $13.98, with an estimated average price of $11.1. The stock is now traded at around $11.97. The impact to a portfolio due to this purchase was 0.92%. The holding were 1,750,000 shares as of .

Artal Group S.A. initiated holding in Ascendis Pharma A/S. The purchase prices were between $62.15 and $129.99, with an estimated average price of $86.75. The stock is now traded at around $122.34. The impact to a portfolio due to this purchase was 0.62%. The holding were 125,000 shares as of .

Artal Group S.A. initiated holding in Mirati Therapeutics Inc. The purchase prices were between $42.42 and $78.95, with an estimated average price of $67.65. The stock is now traded at around $67.42. The impact to a portfolio due to this purchase was 0.54%. The holding were 175,000 shares as of .

Artal Group S.A. initiated holding in WAVE Life Sciences Ltd. The purchase prices were between $32.69 and $47.91, with an estimated average price of $40.58. The stock is now traded at around $27.22. The impact to a portfolio due to this purchase was 0.41%. The holding were 250,000 shares as of .

Artal Group S.A. added to a holding in Acceleron Pharma Inc by 57.14%. The purchase prices were between $39.06 and $48.05, with an estimated average price of $43.83. The stock is now traded at around $41.19. The impact to a portfolio due to this purchase was 1.18%. The holding were 1,650,000 shares as of .

Artal Group S.A. added to a holding in Blueprint Medicines Corp by 41.67%. The purchase prices were between $48.7 and $86.6, with an estimated average price of $73.56. The stock is now traded at around $82.35. The impact to a portfolio due to this purchase was 0.85%. The holding were 850,000 shares as of .

Artal Group S.A. added to a holding in InflaRx NV by 65.00%. The purchase prices were between $31.16 and $48.62, with an estimated average price of $37.15. The stock is now traded at around $43.09. The impact to a portfolio due to this purchase was 0.52%. The holding were 825,000 shares as of .

Artal Group S.A. added to a holding in The Medicines Co by 75.00%. The purchase prices were between $17.86 and $28.02, with an estimated average price of $23.46. The stock is now traded at around $32.11. The impact to a portfolio due to this purchase was 0.36%. The holding were 700,000 shares as of .

Artal Group S.A. added to a holding in Dicerna Pharmaceuticals Inc by 86.53%. The purchase prices were between $9.74 and $14.65, with an estimated average price of $11.47. The stock is now traded at around $11.06. The impact to a portfolio due to this purchase was 0.28%. The holding were 979,275 shares as of .

Artal Group S.A. added to a holding in Solid Biosciences Inc by 140.00%. The purchase prices were between $7.19 and $32.37, with an estimated average price of $16.87. The stock is now traded at around $9.76. The impact to a portfolio due to this purchase was 0.27%. The holding were 1,200,000 shares as of .

Artal Group S.A. sold out a holding in Clementia Pharmaceuticals Inc. The sale prices were between $11.64 and $26.17, with an estimated average price of $18.43.

Artal Group S.A. sold out a holding in AnaptysBio Inc. The sale prices were between $61.38 and $75.39, with an estimated average price of $69.01.

Artal Group S.A. sold out a holding in Homology Medicines Inc. The sale prices were between $19.76 and $29.57, with an estimated average price of $24.76.

Artal Group S.A. sold out a holding in Momenta Pharmaceuticals Inc. The sale prices were between $10.47 and $15.1, with an estimated average price of $12.75.

Artal Group S.A. sold out a holding in Marinus Pharmaceuticals Inc. The sale prices were between $2.87 and $4.28, with an estimated average price of $3.59.

Artal Group S.A. sold out a holding in Y-mAbs Therapeutics Inc. The sale prices were between $18.21 and $26.21, with an estimated average price of $21.95.